StockData

Abbott Laboratories vs Johnson & Johnson

ABT and JNJ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABT and JNJ compare

Johnson & Johnson is the larger company, worth 3.7 times as much as Abbott Laboratories ($671B against $181B).

On earnings, Abbott Laboratories is cheaper: it trades at 33.7× trailing earnings, against 42.3× for Johnson & Johnson.

Abbott Laboratories grew revenue faster over the last twelve months (8.1% versus 7.8% for Johnson & Johnson).

Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 11.6% at Abbott Laboratories.

Both pay dividends: Abbott Laboratories yields 2.4% and Johnson & Johnson 1.9%.

Abbott Laboratories scores higher on the StockData Score (14 against 12 for Johnson & Johnson), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABTJNJ
Size and price
Market cap$181B$671B
Share price$104.71$278.70
Change, 1 year−19.8%42.2%
Change, 5 years−16.8%75.1%
Beta (5Y)−0.45−0.30
Employees115K138K
StockData Score
Total score14 (better)12
Valuation score1 (better)0
Growth score33
Performance score34 (better)
Health score4 (better)3
Dividend score3 (better)2
Valuation
P/E33.7× (better)42.3×
P/S3.9× (better)6.8×
P/B3.5× (better)8.2×
EV/EBITDA28.4×26.0× (better)
P/FCF23.2× (better)32.6×
PEG–2.36
FCF yield4.3% (better)3.1%
Fair value$78.22$150.10
Margin of safety−33.9% (better)−85.7%
Growth
Revenue growth (TTM)8.1% (better)7.8%
Revenue growth, 5Y average5.1% (better)2.7%
Net income growth (TTM)−61.2%−35.9% (better)
EPS growth (TTM)−61.1%−36.4% (better)
EPS growth, 5Y average8.3%14.9% (better)
Profitability
Gross margin56.6%67.6% (better)
Operating margin15.8%–
Net margin11.6%16.2% (better)
FCF margin16.8%20.7% (better)
Return on equity10.7%20.0% (better)
Return on invested capital7.9%–
Financial health
Debt / equity0.640.55 (better)
Net debt / EBITDA3.681.02 (better)
Interest coverage9.6×–
Current ratio1.38 (better)1.02
Altman Z-score3.255.18 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Dividend yield2.4% (better)1.9%
Payout ratio78.5%–
Years of dividend growth316 (better)
Dividend growth, 5Y average–5.2%
Buyback yield1.0%1.2% (better)
Shareholder yield3.4% (better)3.1%
Ownership
Held by institutions79.8%74.8%
Held by insiders0.50%0.04%
Insider net buying, 12 months−$43.3M (better)−$154M
Superinvestors holding26 (better)
Short interest, % of float1.1%0.71%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.